Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10595406 | Bioorganic & Medicinal Chemistry Letters | 2013 | 6 Pages |
Abstract
Compounds containing a quinuclidine scaffold are promising drug candidates for pharmacological management of the central nervous system (CNS) pathologies implicating nAChRs. We have carried out binding affinity and in-silico docking studies of arylmethylene quinuclidine-like derivatives at the α4β2 receptor using in-vitro receptor binding assay and comparative modeling, respectively. We found that introducing a hydrogen-bond acceptor into the 3-benzylidene quinuclidine derivative resulted in a 266-fold increase in binding affinity and confers agonism properties. By contrast, addition of a phenyl group to 3-benzylidene quinuclidine derivative only results in an 18-fold increase in binding affinity, without conferring agonism. We also found that docking into the orthosteric binding site of the α4β2 nAChR is consistent with the fact that the basic nitrogen atom donates a hydrogen-bond to the carbonyl group of the highly conserved Trp-149, as initially observed by Dougherty and co-workers.1 The experimentally-observed trend in binding affinity at both α4β2 and α3β4 nAChRs was accurately and independently confirmed by quantum mechanics (QM)-polarized docking. The reduction in binding affinity to the α3β4 subtype primarily results from a dampening of both coulombic and cation-Ï interactions.
Keywords
nAChRroot-mean-squared-deviationAChBPQPLDPDBRMSDROCMECAChAgonismAcetylcholineBindingProtein DatabankCNSStandard PrecisionExtra Precisioncentral nervous systemenrichment factorHomology modelingReceiver operating characteristic curveNicotineAcetylcholine-binding proteinNICnicotinic acetylcholine receptor
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
David C. Kombo, Vladimir P. Grinevich, Terry A. Hauser, Serguei Sidach, Merouane Bencherif,